Latest Spasmodic torticollis Stories
GREENSBORO, N.C., April 13 /PRNewswire/ -- Merz Pharmaceuticals announces that results from several new studies examining XeominÂ® (incobotulinumtoxinA), a botulinum neurotoxin type A (free from complexing proteins), also referred to as NT 201, will be presented today at the 62nd American Academy of Neurology (AAN) annual meeting in Toronto, Canada.
WASHINGTON, June 19 /PRNewswire/ -- The Center for Laser Surgery, Washington, DC has announced the availability of Dysport, abobotulinum toxin-A.
-Second Data Set Presented at MDS- PARIS, June 9 /PRNewswire/ -- Results from three placebo controlled studies conducted to assess NT-201 in upper limb post-stroke spasticity, pre-treated cervical dystonia, and treatment-naive cervical dystonia patients represent the second data set presented at the Movement Disorder Society (MDS) 13th Annual International Congress in Paris, France.
--First of 2 data sets to be released-- PARIS, June 8 /PRNewswire/ -- Results from two randomized, active-controlled clinical trials in patients with blepharospasm and cervical dystonia -- one placebo-controlled spasticity trial and one upper limb spasticity trial -- were presented at the Movement Disorder Society (MDS) 13th annual International Congress in Paris, France.
US regulators warned consumers and doctors on Thursday about potentially deadly complications that can arise from off-label use of Allergan Incâ€™s Botox and similar drugs.
SEATTLE, April 28 /PRNewswire/ -- Results from two prospective, double-blind placebo controlled multi-center studies in patients with cervical dystonia and blepharospasm, and pooled European efficacy and safety data in patients with focal dystonia and upper limb spasticity will be presented at the American Academy of Neurology's (AAN) 61st annual meeting in Seattle.
New Patient Video Vignettes and Mechanism of Action 3-D Video Illustrate the Versatility and Application of BOTOX(R) Across Several Approved Indications IRVINE, Calif., April 15 /PRNewswire-FirstCall/ -- As part of the nearly 20-year milestone since the first approved indications by the U.S.
New Prescription Product Increases Length, Thickness and Darkness of Eyelashes IRVINE, Calif., Dec. 26 /PRNewswire-FirstCall/ -- Allergan, Inc. (NYSE: AGN) today announced the U.S.
Regulatory News: Ipsen (Paris:IPN) today announced that the U.S.
BOTOX(R) is an important medicine that over the last 15 years of clinical use has helped millions of patients with serious medical conditions worldwide.